November 15, 2026

| | |
|---|---|
| To,<br>The Department of Corporate Services,<br>**BSE Limited,**<br>Phiroze Jeejeebhoy Towers,<br>Dalal Street, Fort,<br>Mumbai – 400001<br>**Scrip Code – 544709** | To,<br>The Listing Department,<br>**National Stock Exchange of India Limited,**<br>Exchange Plaza, C-1, Block G,<br>Bandra Kurla Complex, Bandra (E),<br>Mumbai – 400051<br>**Symbol – GAUDIUMIVF** |
| **ISIN:** INE0P8B01020 | **ISIN:** INE0P8B01020 |

**Subject: Investor Presentation on the Financial Results of the Company for the quarter and half year ended September 30, 2026**

Dear Sir/Ma'am,

Pursuant to the Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith the Investor Presentation on highlights of the Financial Results of the Company for the quarter and half year ended September 30, 2026.

This disclosure will also be hosted on the website of the Company at www.gaudiumivfcentre.com.

Kindly take the information on record

Thanking You,

Yours faithfully,

**For and on behalf of Gaudium IVF and Women Health Limited**

MANIKA KHANNA
Digitally signed by MANIKA KHANNA
Date: 2026.11.15 15:44:30 +05'30'

**Dr. Manika Khanna**
**Chairperson and Managing Director**
**DIN: 07090907**

**Encl: a/a**



# GAUDIUM IVF AND WOMEN HEALTH LIMITED

## INVESTOR PRESENTATION

## Q2 & H1FY27

# Safe Harbour

This document is prepared only for information purpose and do not solicit/recommend/guide for any Investment/Buy-Sell in any financial instrument of **Gaudium IVF and Women Health Limited ("Gaudium")** and/or any of its subsidiary company or associate company. Neither **Gaudium** nor any of its group company/subsidiary Company/ associate company , directors, or employees related person are responsible for any gains/loss arising to any person/body corporate due to any such transaction as stated above.

This document may contain certain forward-looking statements. These forward-looking statements can generally be identified by words or phrases such as "aim", "anticipate", "believe", "expect", "estimate", "intend", "objective", "plan", "project", "shall", "will", "will continue", "will pursue" or other words or phrases of similar meaning. Similarly, statements that describe strategies, objectives, plans or goals are also forward-looking statements. **Gaudium** cannot assure investors that the expectation reflected in these forward-looking statements will prove to be correct. Given these uncertainties, investors are cautioned not to place undue reliance on such forward-looking statements and not to regard such statements as a guarantee of future performance.

# Table of Contents


## 01

### About Us

- Company at a Glance
- Journey of Gaudium IVF
- Process Flow - IVF Treatment
- AI-Powered End-to-End Fertility Solutions
- Key Clinical Highlights
- Strategic Milestones

## 02

### Business Overview

- IVF Industry Overview
- Growth Drivers in the Industry
- Entry Barriers in Industry
- Our Moat, Our Momentum
- Pan-India Presence
- Serving Patients Around The Globe
- Center/Hub Wise Details
- AI That Makes the Difference
- Infrastructure & Facilities at Centers
- 360° Customer Acquisition
- Rapid Growth Strategy
- Board Of Directors

## 03


### Q2 & H1FY27 Financial Performance

- Financial Snapshot
- Standalone Financial Statements
- Consolidated Financial Statements

## 04

### Annexures

- Shareholding Pattern & Key Market Data
- Case Studies
- Awards and Recognitions
- CSR Initiatives
- Patient Testimonials




# ABOUT US

# Company at a Glance

Founded: 2009 by **Dr Manika Khanna and Dr. Peeyush Khanna**

Network: **9 Hubs + 38 Spokes** | Presence: **9 States across India**

## Services Revenue Split




## AI Initiatives to help improve success rate:

**SiD & ERICA**

**Success Rates:**

First Attempt - **62%**

**Success Rates:**

Multiple Attempts - **85%**

No of OPU: **889**

Average Revenue Per Patient: **Rs. 3.07 Lakhs**

# Journey of Gaudium IVF

gaudium IVF
Delivering Motherhood Dreams

## PHASE 01

### 2009 – 2017

**Establishing a Strong Foothold**

Establishing presence in North India

- **2009** Janakpuri Hub
- **2016** Greater Kailash Hub
- **2017** Ludhiana Hub

## PHASE 02

### 2019 – 2024

**Broadening Market Reach**

Extended presence across multiple cities and regions.

- **2019** Patna Hub
  Spokes at Bihar, Srinagar & Punjab
- **2022** Mumbai Hub
  Spokes at Mumbai
- **2023** Bangalore Hub
- **2024** Srinagar Hub

## PHASE 03

### 2026

**Next Phase of Expansion**

Successful public-market listing, coupled with continued expansion of centres.

- **2026**
- BSE & NSE Listing
- South Delhi Hub
- Gurgaon Hub

**Upcoming Expansion**

**Nagpur Hub**

*Centre ready; licence filed, approval awaited*

# Process Flow - IVF Treatment

A seamless, patient-centric journey supported by clinical excellence and care at every step

## 1 Conversion of Lead

- Lead Generated & Follow up
- Lead Re-engaged
- Patient Walk-in
- Registration of Patient, Free OPD and Ultrasound
- If Interested
- Discussion with finance counselor on package and payment terms

## 2 IVF Process Starts

- **Injections**
  Package amount either paid in full or in installment as per the payment terms
- Ovum Pick Up (OPU)
- Insemination & Embryo Formation
- Freeze All
- Embryo Transfer (ET)
- **Success / Failure of ET**
  (Captured in patient file)
  - If Negative
    - Subsequent Thaw ET - Separate package
    - In case of miscarriage
    - IVF Successful
  - If Positive
    - IVF Successful

## 3 Hospital & Post Care

- Delivery Package (pricing varies basis room category.
- Routine Support (from month 4-9, including vaccines etc)

Support available only at **Delhi Janakpuri Centre**

# AI-Powered End-to-End Fertility Solutions

gaudium IVF
Delivering Motherhood Dreams



Advanced IVF Treatment




Male Infertility




Ovulation Induction




Egg Freezing



ERICA



SiD



Infertility Surgeries




Frozen Embryo Transfer



Embryo Freezing



Gynae Consultation




Laparoscopy for Infertility



PCOD/PCOS

# Key Clinical Highlights



**62%**

**Success rate at one attempt**

Early results show an **8-9% increase** with **SiD** & ERICA.

### SOP-Driven Organization
From clinical, embryology and doctors to housekeeping.

### AI-Powered IVF
First in India, 2nd outside the US to introduce AI tools SiD & ERICA.

### In-House Trained Talent
Clinicians and embryologists trained within Gaudium.

### Constant Innovation
Especially for patients with multiple failed IVFs.

### Signature Labs & IVF
State-of-the-art Gaudium Signature laboratories and IVF.

### MANTRANA
Dedicated emotional counselling support for patients.

### ART Law Compliance
Strict adherence to the ART (Regulation) Act.

### Global Patient Base
Successfully treated patients from 30+ countries.

### IVF Insurance & Financial Support
Partnership with Carepay (Carecoin Technologies Private Limited) and Care Health Insurance, providing eligible couples coverage of up to ₹3 lakh, subject to policy terms.

# Strategic Milestones



*India's*

## FIRST Listed IVF Company

IVF company to be listed on the stock market, marking a historic milestone in the fertility care industry.

## FIRST No. 1 IVF Clinic


IVF clinic ranking as per the Health Survey conducted by Times of India.

## FIRST AI in Fertility Care

IVF chain to introduce Artificial Intelligence in infertility treatment.

## FIRST European Quality Award

IVF company to receive the European Quality Award for the highest quality standard.




# BUSINESS OVERVIEW

# IVF Industry Overview

Strong demographic tailwinds, significant treatment gap and evolving industry structure create a long runway for scalable growth

## MARKET SIZE & GROWTH

**India IVF Market Size (USD Billion)**




Global IVF market projected to grow from **USD 27.49Bn to USD 54.60Bn** at **~7.1%** CAGR

India's share in the global IVF market expected to increase from **~4.8%** to **~8.3%**

India remains among the **fastest-growing IVF markets globally**, outpacing developed markets

## SIGNIFICANT UNDERPENETRATION

**Huge gap between need and treatment**

**~27.5 Mn**
Infertile couples in India

VS

**~300,000**
IVF cycles annually

Indicates **<2%** penetration of addressable demand

Only **~1 in 50** couples who require IVF currently access treatment

## STRUCTURAL SUPPLY GAP

IVF access remains concentrated in
**Top 8 Metro cities**
Delhi NCR, Mumbai, Ahmedabad, Chennai, Kolkata, Hyderabad, Bengaluru, Pune



Industry transitioning from **fragmented standalone clinics** to organized platforms

Regulatory tightening (ART Act) accelerating shift towards **compliant, scalable players**

*Sources: Gaudium IVF RHP, Infomerics Analytics & Research Reports*

# Growth Drivers in the Industry

gaudium IVF
Delivering Motherhood Dreams



## DECLINING FERTILITY RATES

- India's fertility rate has fallen below replacement levels, indicating structural demand
- Continued decline expected, increasing reliance on assisted reproductive treatments



## DELAYED PARENTHOOD

- Rising age at marriage and first childbirth, particularly in urban India
- Increasing number of patients seeking fertility treatment post age 30–35



## LIFESTYLE & HEALTH FACTORS

- Rising incidence of PCOS, obesity, stress, and hormonal disorders
- Male infertility contributes to ~50% of overall cases



## IMPROVING AWARENESS & ACCEPTANCE

- Growing awareness and reduced stigma around IVF treatment
- Increased adoption driven by digital outreach and social normalization



## TECHNOLOGY-DRIVEN OUTCOMES

- Advancements in AI-enabled embryo selection, genetic testing, and cryopreservation
- Improving success rates, patient conversion, and confidence via AI-driven technology integration



## MEDICAL TOURISM ADVANTAGE


- IVF treatment in India costs ~70–80% lower than developed markets
- Positioning India as a global destination for fertility treatment



## REGULATORY TAILWIND

- ART Act driving standardization, transparency, and compliance
- Accelerating consolidation in favour of organized players

# Entry Barriers in Industry





Navigating Key Industry Barriers → Built a Scalable Fertility Platform


Every barrier above is a moat Gaudium IVF already crossed
positioning the company as a category leader with sustainable competitive advantage.

# Our Moat, Our Momentum

Eleven strengths built over **15+ years** that create a compounding advantage for Gaudium IVF



# Pan-India Presence




**9 Hubs**
Comprehensive Care & Specialists


**38 Spokes**
Extending access to Quality fertility care

**35**
**Domestic**

**3**
**International**

Sydney
Nigeria
Paris

# Serving Patients Around The Globe




Delivering world – class fertility care to patients across the globe

**3 INTERNATIONAL SPOKES**

**Sydney | Nigeria | Paris**

# AI That Makes the Difference

Gaudium is among the few IVF providers in India to deploy both SiD and ERICA, creating an integrated AI-assisted clinical workflow that supports improved outcomes and consistent success across centres.


## SiD

**AI POWERED SPERM SELECTION**

Selecting the best sperm for fertilisation (ICSI)


### How It Works

- Analyses sperm in real time using AI-based imaging
- Evaluates key parameters including motility and movement patterns
- Assigns an objective score to each sperm
- Enables selection of the highest-quality sperm with greater consistency




### Why It Matters

- Reduces subjectivity in sperm selection
- Improves fertilisation and embryo quality
- Ensures consistency across centres





## ERICA

AI Powered embryos based on implantation

### How It Works

- Analyses embryo images using advanced algorithms
- Evaluates multiple developmental parameters
- Identifies features not visible to the human eye
- Classifies embryos based on implantation potential




### Why It Matters

- Improves embryo selection accuracy
- Supports better clinical outcomes
- Reduces reliance on additional invasive testing

## The Integrated AI Advantage

- **Higher Success Rates** — Better selection leads to improved outcomes
- **Standardised Outcomes** — Reduced variability across centres
- **Reduced Subjectivity** — Data-driven decision making at critical stages
- **Scalable Clinical Quality** — Enables expansion without compromising outcomes
- **Sustainable Technology Advantage** — Integrated AI systems support long-term differentiation

# Infrastructure & Facilities at Centers



## Clinical Facilities

- **Consultation rooms** for patient and doctor engagement for preliminary examination
- Advanced andrology lab equipped for **semen analysis and sperm processing.**
- **Embryology lab** for **egg fertilization**, embryo culture, and **embryo transfer**
- **Surgical suite** for **egg retrieval** and embryo transfer



## Specialized Equipment's

- **Incubators** to help embryos grow and develop properly during the IVF process
- **Laminar flow hoods** to protect against dust and other particles, making it safer for handling eggs and embryos.
- **Centrifuge** to maintain the temperature and keep semen and embryos safe from dust and airborne germs.
- **A cryo storage tank** is used to **freeze and store fertilized eggs**

# 360° Customer Acquisition

- Reach Intent-Based Audience
- Outreach in Tier II and Tier III cities
- Aggressive social media marketing
- CXO Branding to build Dr. Manika as Brand Ambassador
- Performance Marketing and SEO







- Historically strong Patient Network
- Well-established Doctor network

- Media Relations
- Press Conferences
- Interviews
- Featured Articles
- Corporate Announcements
- Influencer and Celebrity Partnerships








- ATL - TV, Outdoor, Newspapers
- BTL - Chemist Promotion, Road Shows
- Strong Brand messaging

# Rapid Growth Strategy



## FY27

**2** **Hubs Inaugurated**
South Delhi & Gurgaon

**7** **Upcoming Hubs**

+

**Nagpur Hub Launching Soon**

## FY28

**8 new centers**

## FY29

**1 new center**

- The addition of **new centers** will enhance Gaudium IVF's **pan-India brand visibility**
- Increased **customer footfall** is expected to drive higher **revenues and strengthen key financial parameters**
- This expansion will **position Gaudium IVF** among the leading large players in the industry

# Board Of Directors



**Dr. Manika Khanna,**
**Promoter & CMD**

Holds an **MBBS (Gold Medallist)** and **MD in Obstetrics** & Gynecology from Maharaja Sayajirao University of Baroda. She has completed training in **Advanced Gynecological** Endoscopic Surgery in **Kiel, Germany,** and in advanced gynecological endoscopy from Melbourne IVF Gujarat Private Limited.

She brings over 16 years of experience in IVF treatment.

**Awards: Delhi Ratna Award (2008) and the Women Excellence Award (2016).**



**Dr. Peeyush Khanna,**
**Promoter & WTD**

Holds an MBBS from Manipal Academy of Higher Education and a Diploma in Child Health from University of Delhi (1999) and has been associated with Gaudium since its incorporation and brings over **10 years of experience in pediatrics and child health.**

He currently leads the **Pediatric Division** and supports the Company's operations across India.

**Awards: Secretary Appreciation Award from the Delhi Medical Association (2016), the Organizer Award at the Pediatric Conference of North India (2015), Recognize the Genius' award (2021)**



**Mr. Vishad Khanna**
**Director**



**Mr. Rajesh C. Bhojani**
**Independent Director**



**Mr. Brajesh S Bhadauria**
**Independent Director**




**Mr. Suresh Marpu**
**Independent Director**

# Center/Hub Wise Details

| Center Wise Details | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| **Particulars** | **Delhi – Janakpuri** | **Delhi – Chander Nagar** | **Ludhiana** | **Patna** | **Mumbai** | **Bengaluru** | **Srinagar** | **South Delhi** | **Gurgaon** |
| **State** | Delhi NCR | Delhi NCR | Punjab | Bihar | Maharashtra | Karnataka | Jammu & Kashmir | Delhi | Haryana |
| **Date of Commencement** | 2009* | 2016* | 2017# | 2019* | 2022 | 2023 | 2024 | 2026 | 2026 |
| **Owned/Rental** | **Rental** | | | | | | | | |
| **No of Beds** | 15 | 3 | 5 | 5 | 9 | 7 | 7 | 4 | 4 |
| **No of OT** | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| **IVF Facility** | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| **ART Level** | Level-2 | Level-1 | Level-2 | Level-2 | Level-2 | Level-2 | Level-2 | Level- 2 | Level-2 |


**Gaudium IVF and Gynae Solutions, a proprietary firm of Dr. Manika Khanna, was acquired by the company in accordance with the main object clause as mentioned in the Memorandum of Association.*


*# Pursuant to Slump Sale Agreement dated February 02, 2023, executed among Gaudium IVF and Women Health Private Limited (the Purchaser), Gaudium Bawa IVF (the Partnership Firm), Dr. Manika Khanna (Partner 1), Dr. Sayesha Bawa (Partner 2), and Gaudium IVF and Women Health Private Limited (Partner 3), the company acquired the business of Gaudium Bawa IVF.*





# Q2 & H1 FY27 FINANCIAL PERFORMANCE

# Q2 FY27 Financial Snapshot









***Note:** Margin Ratios are based on PAT from Continuing Operations.*

# H1 FY27 Financial Snapshot


## Revenue From Operations (Rs. Lakhs)





## Operating EBITDA (Rs. in Lakhs)




## PAT (Rs. in Lakhs)




## PAT Margin




***Note:** Margin Ratios are based on PAT from Continuing Operations.*

# Financial Statement (Rs. Lakhs) Standalone

| Income statement | Q2 FY27 | Q2 FY26 | YOY | Q1 FY27 | QOQ | H1 FY27 | H1 FY26 | YOY | FY26 |
|---|---|---|---|---|---|---|---|---|---|
| **Revenue from Operations** | **2805.68** | **2294.58** | **22.27%** | **1367.73** | **105.13%** | **4173.41** | **3521.90** | **18.50%** | **7157.85** |
| **EBITDA (Ex. Other Income)** | **1172.84** | **1327.65** | **(11.66%)** | **217.40** | **439.49%** | **1390.24** | **1747.22** | **(20.43%)** | **3456.60** |
| *EBITDA Margins %* | *41.80%* | *57.86%* | *(1606) bps* | *15.89%* | *2591 bps* | *33.31%* | *49.61%* | *(1630) bps* | *48.29%* |
| **PAT** | **819.97** | **902.54** | **(9.15%)** | **166.35** | **392.93%** | **986.31** | **1137.23** | **(13.27%)** | **2228.77** |
| *PAT Margins %* | *29.23%* | *39.33%* | *(1010) bps* | *12.16%* | *1707 bps* | *23.63%* | *32.29%* | *(866) bps* | *31.14%* |

## Comments:

Revenue from operations grew strongly YoY in Q2 FY27. Margins narrowed due to the marketing strategy and costs associated with rolling out new hubs, which are still in their early ramp-up phase and carry high fixed costs.

***Note:*** *For detailed financial information, please refer to the financial results filed with the stock exchanges.*

# Financial Statement (Rs. Lakhs) Standalone

| Balance Sheet | 30-Sep-26 | 31-Mar-26 |
|---|---|---|
| Equity Share Capital | 3,639.34 | 3,639.34 |
| Other Equity | 12,262.05 | 11,287.14 |
| **Net Worth** | **15,901.39** | **14,926.48** |
| **Non-Current Liabilities** | | |
| Borrowings | - | - |
| Lease Liabilities | 1,529.10 | 128.26 |
| Others | 134.97 | 95.63 |
| **Current Liabilities** | | |
| Borrowings | - | 2,109.95 |
| Lease Liabilities | 260.44 | 21.28 |
| Trade payables | 123.39 | 283.25 |
| Others | 470.69 | 293.74 |
| **Total Source of Funds** | **18,419.97** | **17,858.59** |

| Balance Sheet | 30-Sep-26 | 31-Mar-26 |
|---|---|---|
| **Non-Current Assets** | | |
| Property, Plant and Equipment | 716.75 | 534.67 |
| Right of Use Asset | 2,050.89 | 121.62 |
| Goodwill | 13.82 | 13.82 |
| Other Intangible Assets | 2,241.37 | 865.28 |
| Intangible Assets Under Development | - | 1,196.83 |
| Others | 7,394.46 | 9,138.08 |
| **Current Assets** | | |
| Inventories | 203.59 | 229.86 |
| Trade Receivables | 3,283.39 | 4,260.42 |
| Cash and Cash Equivalents | 2,020.45 | 853.69 |
| Others | 495.25 | 644.32 |
| **Application of Funds** | **18,419.97** | **17,858.59** |

| Cash Flows (Rs in Lakhs) | 30-Sep-26 | 30-Sep-25 |
|---|---|---|
| Cash Flow Generated from/(Used in) Operating Activities | 2,240.42 | 169.68 |
| Cash Flow from/(Used in) Investing Activities | 1,509.18 | (446.03) |
| Cash Flow from/(Used in) Financing Activities | (2,582.84) | 248.20 |
| Net Increase/(Decrease) in Cash and Cash Equivalents | 1,166.76 | (28.15) |
| Opening Cash and Cash Equivalents | 853.69 | 686.67 |
| Closing Cash and Cash Equivalents | 2,020.45 | 658.52 |

***Note:*** *For detailed financial information, please refer to the financial results filed with the stock exchanges.*

# Financial Statement (Rs. Lakhs) Consolidated

| Income statement | Q2 FY27 | Q2 FY26 | YOY | Q1 FY27 | QOQ | H1 FY27 | H1 FY26 | YOY | FY26 |
|---|---|---|---|---|---|---|---|---|---|
| **Revenue from Operations** | **3,741.11** | **3,173.04** | **17.90%** | **1,937.66** | **93.07%** | **5,678.77** | **4,949.88** | **14.73%** | **10,435.70** |
| **EBITDA (Ex. Other Income)** | **1,346.95** | **1,376.20** | **(2.13%)** | **242.41** | **455.65%** | **1,589.36** | **1,895.23** | **(16.14%)** | **3,770.40** |
| *EBITDA Margins %* | *36.00%* | *43.37%* | *(737) bps* | *12.51%* | *2349 bps* | *27.99%* | *38.29%* | *(1030) bps* | *36.13%* |
| **PAT** | **941.31** | **937.91** | **0.36%** | **177.59** | **430.04%** | **1,118.91** | **1,250.56** | **(10.53%)** | **2,448.85** |
| *PAT Margins %* | *25.16%* | *29.56%* | *(440) bps* | *9.17%* | *1599 bps* | *19.70%* | *25.26%* | *(556) bps* | *23.47%* |

## Comments:

Revenue growth in Q2 FY27 was driven mainly by the IVF business. EBITDA and PAT remained largely flat due to the marketing strategy and costs associated with rolling out new hubs, which are still in their early ramp-up phase and carry high fixed costs. These were partly offset by hospital and pharmacy businesses.

***Note:*** *For detailed financial information, please refer to the financial results filed with the stock exchanges.*


# Financial Statement (Rs. Lakhs) Consolidated

| Balance Sheet | 30-Sep-26 | 31-Mar-26 |
|---|---|---|
| Equity Share Capital | 3,639.34 | 3,639.34 |
| Other Equity | 12,675.20 | 11,590.87 |
| **Net Worth** | **16,314.54** | **15,230.21** |
| **Non-Current Liabilities** | | |
| Borrowings | - | - |
| Lease Liabilities | 1,529.10 | 128.26 |
| Others | 140.75 | 99.25 |
| | | |
| **Current Liabilities** | | |
| Borrowings | 479.87 | 2,307.48 |
| Lease Liabilities | 260.44 | 21.28 |
| Trade payables | 771.53 | 1,222.92 |
| Others | 546.24 | 301.05 |
| **Total Source of Funds** | **20,042.46** | **19,310.45** |

| Balance Sheet | 30-Sep-26 | 31-Mar-26 |
|---|---|---|
| **Non-Current Assets** | | |
| Property, Plant and Equipment | 922.37 | 746.44 |
| Right of Use Asset | 2,050.89 | 121.62 |
| Goodwill | 13.82 | 37.00 |
| Other Intangible Assets | 2,241.37 | 865.28 |
| Intangible Assets Under Development | - | 1,196.83 |
| Others | 7,269.46 | 9,013.08 |
| | | |
| **Current Assets** | | |
| Inventories | 314.66 | 354.46 |
| Trade Receivables | 4,530.30 | 5,337.93 |
| Cash and Cash Equivalents | 2,048.56 | 878.57 |
| Others | 651.04 | 759.24 |
| **Application of Funds** | **20,042.46** | **19,310.45** |

| Cash Flows (Rs in Lakhs) | 30-Sep-26 | 30-Sep-25 |
|---|---|---|
| Cash Flow Generated from/(Used in) Operating Activities | 1,976.54 | 235.56 |
| Cash Flow from/(Used in) Investing Activities | 1,506.12 | (544.12) |
| Cash Flow from/(Used in) Financing Activities | (2,312.67) | 248.92 |
| Net Increase/(Decrease) in Cash and Cash Equivalents | 1,169.99 | (59.63) |
| Opening Cash and Cash Equivalents | 878.57 | 721.50 |
| Closing Cash and Cash Equivalents | 2,048.56 | 661.87 |


***Note:*** *For detailed financial information, please refer to the financial results filed with the stock exchanges.*



# ANNEXURES

# Shareholding Pattern & Key Market Data

## Shareholding Pattern




## Key Market Data

| | |
|---|---|
| BSE Ticker | 544709 |
| NSE Symbol | GAUDIUMIVF |
| No. of Shares Outstanding* | 7,27,86,884 |
| Share Price** | Rs 111.10 |
| Market Capitalisation (Rs. Cr) | Rs 808.66 |
| Industry | Healthcare Service Provider |

** As on Sept 2026 | ** BSE Share price as on 30th Sept, 2026*

# Case Studies - Our Amazing Successes



**10**

**Remarkable Journeys**


Real outcomes achieved against the toughest odds, with science & care

- **2009 – A Historic First:** 51-year-old achieved a successful IVF & live birth with her own eggs.
- **2012 – 15 Failed IVFs:** 15 prior failures (5 USA, 5 Delhi, 5 Mumbai); conceived & widely covered by media.
- **2020 – Surrogacy Success:** A well-known Bollywood actress with APLA syndrome became a mother via surrogacy.
- **Guinea – Complex Case:** 42-year-old with hypertension, diabetes & multiple fibroids achieved motherhood.
- **USA – Via US Embassy:** 5 prior IVFs & 6 miscarriages — her miracle baby at Gaudium.
- **IVIG Therapy Breakthrough:** 8 prior losses; first live birth through innovative IVIG therapy.
- **NRI Couple – 12 Failures:** Success on the 3rd attempt — later a 2nd baby from frozen gametes.
- **1 KG Fibroid:** A successful IVF cycle & live birth with a one-kilogram fibroid.
- **48 & Nine Failures:** Nine prior failed cycles elsewhere; a healthy daughter from frozen eggs.
- **Morbidly Obese – First Try:** A successful self-cycle on the very first attempt.

# Most Awarded IVF Chain in India



India's Most Powerful Symbol of brand Excellence by Power Brand in London, UK




India best practice Award: IVF Chain of the Year 2019 by Frost & Sullivan (USA)




IVF Leader of the Year, India 2023 Award by Gurudev Sri Sri Ravishankar



Former President of India Smt. Pratibha Patil for her outstanding work in the field of infertility



India best practice Award: IVF Chain of the Year 2019 by Frost & Sullivan (USA)



Highly prestigious Civilian Award "Service of Bharat in the field of Health" by Shri Mansukh Mandaviya (Hon'ble Union Minister for Health & Family Welfare




Ranked No. 1 Health Survey Conducted by Times of India



Winner of healthcare brand by Shri S.P. Singh Baghel: Minister of State of Health and Family welfare




European Quality Award by ESQR, Spain 2022



Medical Service Award from Honourable Health Minister of Delhi Sh. Saurabh Bhardwaj

# Additional Recognition Over the Years

gaudium IVF
Delivering Motherhood Dreams

**2021**

### Oxford Academy, UK

Name in Medical Science — Global Women's Health

**2017**

### Times Healthcare Achievers

Rising Stars O&G — Best Speciality Centre

**2017**

### BusinessWorld Awards

Healthcare Personality of the Year – Women

**2016**

### Indian Medical Association

Chikitsa Ratan Award

**2016**

### URS AsiaOne

World's Greatest Leaders in Healthcare

**2016**

### Delhi Medical Association

Women Achiever of the Year

**2015**

### National Healthcare Achievers

Best IVF & Surrogacy Hospital 2015–16

**2014**

### Healthcare Leadership Summit

Best Single-Speciality Hospital - IVF

**2013**

### IVF India Magazine

Best IVF Institute in India

# CSR Initiative

Ladli Foundation Trust
A National Award Winning Non-Profit Organization

## Ladli Shiksha & Swasthya Initiative

Empowering adolescent girls from underserved communities through education access, health literacy and life-skills development - helping build informed choices, stronger confidence and resilient futures.

**2,500+**
Students Reached

**4** Govt. Schools Covered

**11–18 Years**
Target Age Group

**EWS & Marginalized Communities**
Primary Beneficiary Group

**Delhi**
Project Location




## Our 4 Key Interventions

**Education Access:** Provided educational support through school stationery kits aimed at improving classroom preparedness, participation and learning continuity.

**Health & Menstrual Hygiene Awareness:** Delivered structured MHM workshops through trained female educators focused on healthy practices, awareness and creating safe spaces for open dialogue.



**Health Literacy & SRH Education:** Conducted age-appropriate sessions covering reproductive health awareness, personal safety, bodily autonomy and informed decision-making.

**Life Skills & Leadership Development:** Implemented interactive competency-based modules focused on communication, confidence building, leadership and decision-making capabilities.

# Patient Testimonials





















gaudium®
babies

# THANK YOU !

For further queries, Please contact:

gaudium® IVF
Delivering Motherhood Dreams

**Rakesh Kumar Sharma (CFO)**
cfo@gaudiumivfcentre.com

For further queries, Please contact:

ADFACTORS PR
Reputation & Critical Issues Advisory

**Rushabh Shah**
rushabh.shah@adfactorspr.com
M: +91 80821 80182

**Anand Venugopal**
anand.venugopal@adfactorspr.com
M: +91 70218 52071

**Naomi Fernandes**
naomi.fernandes@adfactorspr.com
M: +91 70452 60278